NYSE:EVHEvolent Health Stock Price, Forecast & News

Evolent Health's stock was trading at $6.92 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, EVH shares have increased by 88.7% and is now trading at $13.06.
View which stocks have been most impacted by Coronavirus.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolent Health in the last year. There are currently 3 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Evolent Health.

Evolent Health is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Evolent Health.

Evolent Health Inc (NYSE:EVH) posted its quarterly earnings results on Tuesday, August, 4th. The technology company reported ($0.03) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.17) by $0.14. Evolent Health had a negative net margin of 53.56% and a negative return on equity of 4.29%.
View Evolent Health's earnings history.

Evolent Health updated its FY 2020 After-Hours earnings guidance on Tuesday, August, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $995M - 1.035 billion, compared to the consensus revenue estimate of $977.85 million.

11 Wall Street analysts have issued 12 month price objectives for Evolent Health's shares. Their forecasts range from $8.00 to $20.00. On average, they anticipate Evolent Health's share price to reach $13.56 in the next twelve months. This suggests a possible upside of 3.8% from the stock's current price.
View analysts' price targets for Evolent Health.

News stories about EVH stock have trended very positive recently, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Evolent Health earned a news impact score of 4.0 on InfoTrie's scale. They also gave media coverage about the technology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days.
View the latest news about Evolent Health.

Some companies that are related to Evolent Health include Premier (PINC), Mantech International (MANT), R1 RCM (RCM), Franklin Covey (FC), Jupai (JP), PHI Group (PHIL) and Rainmaker Systems (VCTL).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolent Health investors own include CA (CA), BlackRock (BLK), Universal Insurance (UVE), Endologix (ELGX), Chipotle Mexican Grill (CMG), Energy Transfer LP Unit (ET), Netflix (NFLX), Micron Technology (MU), Advanced Micro Devices (AMD) and Aegean Marine Petroleum Network (ANW).

(EVH) raised $150 million in an IPO on Friday, June 5th 2015. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and Goldman Sachs acted as the underwriters for the IPO and Wells Fargo Securities, William Blair, SunTrust Robinson Humphrey and Leerink Partners were co-managers.

Evolent Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "EVH."

Evolent Health's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (1.36%), DC Investments Management LLC (1.36%), Profit Investment Management LLC (0.24%), Swiss National Bank (0.20%), New York State Common Retirement Fund (0.14%) and Paradigm Capital Management Inc. NY (0.07%). Company insiders that own Evolent Health stock include Doug S Aron, Frank J Williams, Jonathan Weinberg, Kenneth A Samet, Lydia Stone, Michael D'amato, Seth Blackley and Thomas Peterson III.
View institutional ownership trends for Evolent Health.

EVH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Peregrine Capital Management LLC, and US Bancorp DE.
View insider buying and selling activity for Evolent Health.

EVH stock was purchased by a variety of institutional investors in the last quarter, including DC Investments Management LLC, Profit Investment Management LLC, Paradigm Capital Management Inc. NY, New York State Common Retirement Fund, Swiss National Bank, WoodTrust Financial Corp, SeaCrest Wealth Management LLC, and ProShare Advisors LLC. Company insiders that have bought Evolent Health stock in the last two years include Doug S Aron, Kenneth A Samet, Michael D'amato, and Seth Blackley.
View insider buying and selling activity for Evolent Health.

Shares of EVH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EVH stock can currently be purchased for approximately $13.06.

Evolent Health has a market capitalization of $1.12 billion and generates $846.38 million in revenue each year. The technology company earns $-301,970,000.00 in net income (profit) each year or ($0.91) on an earnings per share basis. Evolent Health employs 3,400 workers across the globe.

The official website for Evolent Health is www.evolenthealth.com.

Evolent Health's mailing address is 800 NORTH GLEBE RD SUITE 500, ARLINGTON VA, 22203. The technology company can be reached via phone at 571-389-6000.